Current issue
Journal content
Articles in press
Archive
About the Journal
About the Polish Annals of Medicine
Editorial Board
Abstracting & indexing
Open Access policy
Charges
Affiliated institutions
Contact
Instructions
Peer review process
Guide for authors
Publication ethics
Ethics and Patient Consent
User License
Usage of third party materials
Disclaimer
Statement on Artificial Intelligence
Reviewers
Guide for reviewers
Review Form
REVIEW PAPER
Novel biomarkers of acute kidney injury and chronic kidney disease
1
Department of Pathophysiology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
2
Department of Human Physiology, Faculty of Medicine, University of Rzeszow, Poland
Submission date: 2016-03-21
Acceptance date: 2016-10-18
Online publication date: 2016-11-11
Publication date: 2019-12-15
Corresponding author
Lukasz Dobrek
Department of Pathophysiology, Jagiellonian University Medical College, Czysta 18, Kraków, Poland. Tel.: +48 12 632 90 56; fax: +48 12 632 90 56.
Department of Pathophysiology, Jagiellonian University Medical College, Czysta 18, Kraków, Poland. Tel.: +48 12 632 90 56; fax: +48 12 632 90 56.
Pol. Ann. Med. 2017;24(1):84-91
KEYWORDS
ABSTRACT
Introduction:
Nowadays, laboratory evaluation of renal damage is based on conventional poorly-sensitive and poorly-specific markers, such as serum creatinine, urea and electrolyte levels. This stimulated continuous research on novel biochemical markers suitable for diagnosis and monitoring of acute kidney injury (AKI) and chronic kidney disease (CKD).
Aim:
The aim of this paper was to review available evidence regarding novel biomarkers of kidney damage.
Material and methods:
The review of available literature was conducted, using search terms 'kidney damage biomarker' and 'kidney injury biomarker.'
Results and discussion:
Cystatin C, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, liver-type fatty acid binding protein, selected urinary enzymes (e.g. N-acetyl-bglucosidase) and low-molecular-weight proteins (e.g. b-2 microglobulin) seem to be the most promising biomarkers of both AKI and CKD. In turn, asymmetric dimethylarginine, inflammatory/ fibrosis parameters (e.g. monocyte chemoattractant protein, transforming growth factor-b1) and Klotho-FGF23 axis raise most interest as the most selective markers of CKD.
Conclusions:
Owing continuing progress in nephrology laboratory diagnostics, novel biomarkers of kidney damage are likely to be introduced in routine clinical practice.
Nowadays, laboratory evaluation of renal damage is based on conventional poorly-sensitive and poorly-specific markers, such as serum creatinine, urea and electrolyte levels. This stimulated continuous research on novel biochemical markers suitable for diagnosis and monitoring of acute kidney injury (AKI) and chronic kidney disease (CKD).
Aim:
The aim of this paper was to review available evidence regarding novel biomarkers of kidney damage.
Material and methods:
The review of available literature was conducted, using search terms 'kidney damage biomarker' and 'kidney injury biomarker.'
Results and discussion:
Cystatin C, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, liver-type fatty acid binding protein, selected urinary enzymes (e.g. N-acetyl-bglucosidase) and low-molecular-weight proteins (e.g. b-2 microglobulin) seem to be the most promising biomarkers of both AKI and CKD. In turn, asymmetric dimethylarginine, inflammatory/ fibrosis parameters (e.g. monocyte chemoattractant protein, transforming growth factor-b1) and Klotho-FGF23 axis raise most interest as the most selective markers of CKD.
Conclusions:
Owing continuing progress in nephrology laboratory diagnostics, novel biomarkers of kidney damage are likely to be introduced in routine clinical practice.
CONFLICT OF INTEREST
None declared.
REFERENCES (58)
1.
Ostermann M. Diagnosis of acute kidney injury: Kidney Disease Improving Global Outcomes criteria and beyond. Curr Opin Crit Care. 2014;20(6):581–587.
2.
Ferguson MA, Waikar SS. Established and emerging markers of kidney function. Clin Chem. 2012;58(4):680–689.
4.
Gowda S, Desai PB, Kulkarni SS, Hull VV, Math AAK, Vernekar SN. Markers of renal function tests. North Am J Med Sci. 2010;2(4):170–173.
5.
Urbschat A, Obermuller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 2011;16(suppl 1):S22–S30.
6.
Lameire N, van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365(9457):417–430.
7.
Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756–766.
8.
Winterberg PD, Lu CY. Acute kidney injury: the beginning of the end of the dark ages. Am J Med Sci. 2012;344(4):318–325.
9.
Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–936.
10.
Metcalfe W, Simpson M, Khan IH, et al. Acute renal failure requiring renal replacement therapy: incidence and outcome. Q J Med. 2002;95(9):579–583.
11.
Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204–R212.
12.
Mehta RL, Kellum JA, Shah SV, Mehta RL, Palevsky P. Acute kidney injury network: report on an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
13.
Heung M, Chawla LS. Acute kidney injury: gateway to chronic kidney disease. Nephron Clin Pract. 2014;127(1–4):30–34.
14.
Campbell D, Weir MR. Defining, treating and understanding chronic kidney disease – a complex disorder. J Clin Hypertens (Greenwich). 2015;17(7):514–527.
15.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150.
16.
Yamaguchi J, Tanaka T, Nangaku M. Recent advances in understanding of chronic kidney disease. F1000Research. 2015;4(F1000 Faculty Rev):1212. http://dx.doi.org/10.12688/f10....
17.
Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN – time for reappraisal. Crit Care. 2009;13(3):211–220.
18.
Ricci Z, Cruz DN, Ronco C. Classification and staging of acute kidney injury: beyond the RIFLE and AKIN criteria. Nat Rev Nephrol. 2011;7(4):201–208.
19.
Thomas ME, Blaine C, Dawnay A, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87(1):62–73.
20.
Vasan RS. Biomarkers of cardiovascular disease. Molecular basis and practical considerations. Circulation. 2006;113(19):2335–2362.
21.
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
22.
Schiffl H, Lang SM. Update on biomarkers of acute kidney injury. Moving closer to clinical impact? Mol Diagn Ther. 2012;16(4):199–207.
23.
Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clin Chem Acta. 2015;438:350–357.
24.
Devarajan P, Murray P. Biomarkers in acute kidney injury: are we ready for prime time? Nephron Clin Pract. 2014;127(1–4):176–179.
25.
Tesch GH. Serum and urine biomarkers of kidney disease: a pathophysiological perspective. Nephrology. 2010;15(6):609–616.
26.
Kashani K, Kellum JA. Novel biomarkers indicating repair or progression after acute kidney injury. Curr Opin Nephrol Hypertens. 2015;24(1):21–27.
27.
Charlton JR, Portilla D, Okusa MD. A basic science view of acute kidney injury biomarkers. Nephrol Dial Transplant. 2014;29(7):1301–1311.
28.
Martensson J, Martling CR, Bell M. Novel biomarkers of acute kidney injury and failure: clinical applicability. Br J Anaesth. 2012;109(6):843–850.
29.
Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics. 2006;5(10):1760–1771.
30.
Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73(9):1008–1016.
31.
Waikar S, Bonventre JV. Biomarkers for the diagnosis of acute kidney injury. Curr Opin Nephrol Hypertens. 2007;16(6):557–564.
32.
Thomas AA, Demirjian S, Lane BR, et al. Acute kidney injury: novel biomarkers and potential utility for patient care in urology. Urology. 2011;77(1):5–11.
33.
Siew ED, Ware LB, Ikizler TA. Biological markers of acute kidney injury. J Am Soc Nephrol. 2011;22(5):810–820.
34.
Ostermann M, Philips BJ, Forni LG. Clinical review: biomarkers of acute kidney injury: what are we now? Crit Care. 2012;16(5):233. http://dx.doi.org/10.1186/cc11....
35.
Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80(8):806–821.
36.
Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol. 2015;4(1):57–73.
37.
Perco P, Pleban C, Kainz A, et al. Protein biomarkers associated with acute renal failure and chronic kidney disease. Eur J Clin Invest. 2006;36(11):753–763.
38.
Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2008;48:463–493.
39.
Edelstein CL. Biomarkers of acute kidney injury. Adv Chronic Kidney Dis. 2008;15(3):222–234.
40.
Soni SS, Pophale R, Ronco C. New biomarkers for acute renal injury. Clin Chem Lab Med. 2011;49(8):1257–1263.
41.
Abdallah E, Waked E, Al-Helal B, Asad R, Nabil M, Harba T. Novel troponin-like biomarkers of acute kidney injury. Saudi J Kidney Dis Transpl. 2013;24(6):1111–1124.
42.
Obermüller N, Geiger H, Weipert C, Urbschat A. Current developments in early diagnosis of acute kidney injury. Int Urol Nephrol. 2014;46(1):1–7.
43.
Ho J, Reslerova M, Gali B, et al. Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin J Am Soc Nephrol. 2011;6(10):2340–2346.
44.
Lorenzen JM, Hafer C, Faulhaber-Walter R, et al. Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol Dial Transplant. 2011;26(2):531–537.
45.
Ramesh G, Krawczeski CD, Woo JG, Wang Y, Devarajan P. Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol. 2010;5(3):395–401.
46.
Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis. 2010;17(6):469–479.
47.
Khan Z, Pandey M. Role of kidney biomarkers of chronic kidney disease: an update. Saudi J Biol Sci. 2014;21(4):294–299.
48.
Breit M, Weinberg KM. Metabolic biomarkers for chronic kidney disease. Arch Biochem Biophys. 2016;589:62–80.
49.
Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant. 2012;27(7):2650–2657.
50.
Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737–747.
51.
Heine GH, Seiler S, Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant. 2012;27(8):3072–3081.
52.
Olauson H, Larsson TE. FGF23 and Klotho in chronic kidney disease. Curr Opin Nephrol Hypertens. 2013;22(4):397–404.
53.
Neyra JA, Moe OW, Hu MC. Fibroblast growth factor 23 and acute kidney injury. Pediatr Nephrol. 2015;30(11):1909–1918.
54.
Donate-Correa J, Muros de Fuentes MM, Mora-Fernandez C, Navarro-González JF. Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers. Clin Chem. 2014;60(7):933–940.
55.
Wong MG, Pollock CA. Biomarkers in kidney fibrosis: are they useful? Kidney Int Suppl. 2014;4(1):79–83.
56.
Adiyanti SS, Loho T. Acute kidney injury (AKI) biomarker. Acta Med Indones. 2012;44(3):246–255.
57.
Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013;3(2):957–976.
58.
Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol. 2011;6(11):2567–2572.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
